Avalo Therapeutics vs Entera Bio
AVTX and ENTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVTX and ENTX compare
Entera Bio is the larger company, worth 1.3 times as much as Avalo Therapeutics ($523M against $395M).
Avalo Therapeutics scores higher on the StockData Score (8 against 6 for Entera Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVTX | ENTX |
|---|---|---|
| Size and price | ||
| Market cap | $395M | $523M |
| Share price | $7.37 | $3.02 |
| Change, 1 year | −50.0% | 10.2% |
| Change, 5 years | −99.9% | −12.0% |
| Beta (5Y) | 2.19 | −0.35 |
| Employees | 23 | 20 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.9× (better) | 72.0× |
| FCF yield | – | −2.1% |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | −61.2% | −35.1% (better) |
| EPS growth, 5Y average | – | −17.9% |
| Profitability | ||
| Return on equity | −36.3% (better) | −139% |
| Return on invested capital | – | −966% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 19.31 (better) | 8.98 |
| Altman Z-score | 4.52 | 14.49 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.01% |
| Shareholder yield | 0.00% (better) | −0.01% |
| Ownership | ||
| Held by institutions | 135% | 6.2% |
| Held by insiders | 0.71% | 11.3% |
| Insider net buying, 12 months | −$8.3M | $141K (better) |
| Short interest, % of float | 16.7% | 4.6% |
Go deeper
- AVTX stock overview
- AVTX income statement
- AVTX valuation and score
- ENTX stock overview
- ENTX income statement
- ENTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.